P. Fournel

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Jean‐Yves Douillard, Rafael Rosell, Mario De Lena et al. · The Lancet Oncology · 2006 · 1.6K citations

Surgical Oncology, Cisplatin Versus Observation, Medicine +10

Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

Caroline Charlier, Élodie Perrodeau, Alexandre Leclercq et al. · The Lancet Infectious Diseases · 2017 · 556 citations · Full text

Prognostic Factors, Foodborne Illness, Clinical Features +6

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Corinne Faivre‐Finn, M. Snee, Linda Ashcroft et al. · The Lancet Oncology · 2017 · 548 citations · Full text

Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique–Groupe Français de Pneumo-Cancérologie NPC 95-01 Study

P. Fournel, G. Robinet, P. Thomas et al. · Journal of Clinical Oncology · 2005 · 543 citations

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Julien Mazières, Fabrice Barlési, Thomas Filleron et al. · Annals of Oncology · 2015 · 320 citations · Full text

Medicine, Pathology, Her2-targeted Drugs +8